24/06/08

Risk-averse researchers put mothers’ lives at risk

A pregnant woman in India Copyright: Flickr/Meanest Indian

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:

You have to credit our authors.
You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
The easiest way to get the article on your site is to embed the code below.

For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

<div class="article-wrap">
<div id="article-introduction">
<h1>Risk-averse researchers put mothers’ lives at risk</h1>
<h4></h4>
</div>
<br />
<br />

<div id="article-body">
<p><span>In 2005, 99 per cent of maternal deaths occurred in the developing world. Despite this, the number of new drugs being created for maternal health is alarmingly small, write Nicholas J. White, Rose M. McGready and Fran</span>ç<span>ois H. Nosten in <em>PLoS Medicine</em>.</span></p>
<p><span>Currently, only 17 drugs are under active development for maternal health. This is in part due to caution about giving newly developed drugs to pregnant women following the thalidomide crisis half a century ago.</span></p>
<p><span>But this caution comes with a price. Malaria poses a particular risk to pregnant women, but there are too few trials of antimalarial drugs in pregnancy.</span></p>
<p><span>The authors write, "Of over 500 antimalarial drug trials conducted between 1966 and December 2006, only 31 evaluated antimalarial treatments (including intermittent preventive treatments) specifically in pregnant women (and 14 of these were from a single centre)."</span></p>
<p><span>Evidence is needed to inform practice, say the authors. Although industry is usually reluctant to underwrite studies of new pregnancy drugs, research centres should be encouraged to study the treatment of diseases in pregnancy. </span></p>
<p><span>We are too risk-averse, and can no longer afford to ignore the problem of how best to treat tropical infectious diseases in pregnancy, the authors say.</span></p>
<p><span><a target="_blank" href="http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371%2Fjournal.pmed.0050133" rel="noopener noreferrer"><span>Link to full article in <em>PLoS Medicine</em></span></a></span></p>

</div>
<div class="quick-links-wrapper">
<h3>You might also like</h3>
[related-articles]
</div>
<p>This article was originally published on <a href="https://www.scidev.net" target="_blank">SciDev.Net</a>. Read the <a href="https://www.scidev.net/global/opinions/risk-averse-researchers-put-mothers-lives-at-risk/" target="_blank">original article</a>.</p>
<script type="text/javascript">
(function(e,t,n,r,i,s,o){e["GoogleAnalyticsObject"]=i;e[i]=e[i]||function(){(e[i].q=e[i].q||[]).push(arguments)},e[i].l=1*new Date;s=t.createElement(n),o=t.getElementsByTagName(n)[0];s.async=1;s.src=r;o.parentNode.insertBefore(s,o)})(window,document,"script","//www.google-analytics.com/ga.js","ga");var _gaq=_gaq||[];var _gaq=_gaq||[];_gaq.push(["_setAccount","UA-3223906-8"],["_trackEvent","article interaction","republished","https://www.scidev.net/global/opinions/risk-averse-researchers-put-mothers-lives-at-risk/",null,true])
</script>
</div>

In 2005, 99 per cent of maternal deaths occurred in the developing world. Despite this, the number of new drugs being created for maternal health is alarmingly small, write Nicholas J. White, Rose M. McGready and François H. Nosten in PLoS Medicine.

Currently, only 17 drugs are under active development for maternal health. This is in part due to caution about giving newly developed drugs to pregnant women following the thalidomide crisis half a century ago.

But this caution comes with a price. Malaria poses a particular risk to pregnant women, but there are too few trials of antimalarial drugs in pregnancy.

The authors write, "Of over 500 antimalarial drug trials conducted between 1966 and December 2006, only 31 evaluated antimalarial treatments (including intermittent preventive treatments) specifically in pregnant women (and 14 of these were from a single centre)."

Evidence is needed to inform practice, say the authors. Although industry is usually reluctant to underwrite studies of new pregnancy drugs, research centres should be encouraged to study the treatment of diseases in pregnancy.

We are too risk-averse, and can no longer afford to ignore the problem of how best to treat tropical infectious diseases in pregnancy, the authors say.

Link to full article in PLoS Medicine